Skip to main content

Table 1 Methodology

From: Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

Study Country Countries Estimated n (sample) for RR analysis Method for RR n (sample) for “outside of range” analysis Population estimation source Population estimation method Calculation of attributable patient-years Equation for calculating attributable patient-years^
Port et al. 2004 [2] US Random sample (n = 17,245) from all 7 DOPPS I countries (N = 52,905) 6 Cox proportional hazards models (one for each factor); a 7th Cox survival model was also used which adjusted for all six HD practices simultaneously. All models were adjusted for age, race, years of ESRD, country & 15 summary comorbid conditions (CAD, CHF, other cardiac disease, PVD, HTN, cerebrovascular disease, DM, lung disease, dyspnea, Hx cancer (active or inactive, excluding skin cancer), GI bleeding in past 12 months, neurologic disease, psychiatric disease, HIV/AIDS, and recurrent skin disease (including gangrene). 1914 prevalent HD patients from US DOPPS II 2001 US Renal Data System Annual Data Report Estimation of the total US HD patient population in 2004 by extrapolation of 2001 data using a 6% annual growth rate The expected gain in patient-years was calculated from the difference in the area under the 5-year survival curves between survival of the US haemodialysis population based on actual current death rates versus projected survival of the US haemodialysis population if all patients currently outside of the six practice guidelines were instead within them. PY = [(N0/L) * FD] + [(N1/L) * (t – (FD/L))],
Assumptions:
• t = 5 years
• L = 0.251 if all patients outside of the target ranges for the six HD practices are brought within these target ranges
• L = 0.30 if there is no change from the current proportion of patients outside the six target ranges
• N0 = 313,000
• N1 = 116,477
Jadoul et al. 2007 [13] Belgium >  20,000 (from all 12 DOPPS I and II countries) Same as US study except: 1 modifiable practice differed (substituted albumin-corrected serum calcium for IDWG); did not adjust for dyspnea 538 prevalent HD patients from Belgian DOPPS II Outpatient HD patient population reported in the 2001 Flemish-speaking and French-speaking registries Estimation of the total Belgian HD patient population in 2006 by extrapolation of 2001 data using a 7.5% annual growth rate Same as US but on Belgian data Same as US except:
• L = 0.113 if all patients outside of the target ranges for the six HD practices are brought within these target ranges
• L = 0.22 if there is no change from the current proportion of patients outside the six target ranges
• N0 = 6373
• N1 = 1591
Piera et al. 2007 [14] Spain >  20,000 (from all 12 DOPPS I and II countries) Same as US study except: 1 modifiable practice differed (substituted albumin-corrected serum calcium for IDWG); did not adjust for dyspnea 613 from Spanish DOPPS II Informe de la Sociedad Española de Nefrología de 2005 Estimation of the total Spanish HD patient population in 2006 by extrapolation of 2005 data using a 5.1% annual growth rate Same as US but on Spanish data Same as US except:
• L = 0.099 if all patients outside of the target ranges for the six HD practices are brought within these target ranges
• L = 0.170 if there is no change from the current proportion of patients outside the six target ranges
• N0 = 20,920
• N1 = 4902
Canaud et al. 2008 [15] France >  20,000 (from all 12 DOPPS I and II countries) Same as US study except: 1 modifiable practice differed (substituted albumin-corrected serum calcium for IDWG); did not adjust for dyspnea 532 from French DOPPS II Bulletin Epidemiologique Hebdomadaire de 2005 Estimation of the total French HD patient population in 2006 by extrapolation of 2005 data using a 5.3% annual growth rate Same as US but on French data Same as US except:
• L = 0.157 if all patients outside of the target ranges for the six HD practices are brought within these target ranges
• L = 0.223 if there is no change from the current proportion of patients outside the six target ranges
• N0 = 31,987
• N1 = 6070
Wikström et al. 2010 [16] Sweden >  20,000 (from all 12 DOPPS I and II countries) Same as US study except: 1 modifiable practice differed (substituted albumin-corrected serum calcium for IDWG); did not adjust for dyspnea 547 prevalent HD patients from Swedish DOPPS II 2003 Swedish Renal Registry Estimation of the total Swedish HD patient population in 2006 by extrapolation of 2003 data using a 4.5% annual growth rate Same as US but on Swedish data Same as US except:
• L = 0.180 if all patients outside of the target ranges for the six HD practices are brought within these target ranges
• L = 0.274 if there is no change from the current proportion of patients outside the six target ranges
• N0 = 2434
• N1 = 769
MONITOR-CKD5 Austria
France
Germany
Italy
Poland
Romania
Slovenia
Spain
Switzerland
United Kingdom*
Not applicable Utilizes published RR rates from various DOPPS studies (see Table 2 for details) 2023 from MONITOR-CKD5 Austria, Poland, Romania, Spain, Switzerland, UK: ERA-EDTA Registry 2014;
France: REIN Rapport Annuel 2014;
Germany: QuaSi-Niere-Bericht 2006–2007;
Italy: RIDT Report 2011–2013;
Slovenia: ERA-EDTA Registry 2013
Estimation of the HD patient population in 2017 in the 10 countries participating in the MONITOR-CKD5 study by extrapolation of 2014 data (except for Germany for which 2006 data were available, and Italy and Slovenia for which 2013 data were available) using a 5% annual growth rate Same as US but on data from 10 European countries Same as US except:
L = 0.170 if all patients outside the target ranges for the six HD practices are brought within these target range
L = 0.203 if there is no change from the current proportion of patients outside the six target ranges
N0 = 303,517
N1 = 66,597
  1. * Included centres in England only.
  2. ^ where t total time period, FD fraction still on dialysis at time t, L annual rate of US haemodialysis patients lost from the haemodialysis population due to death or transfer to transplantation or peritoneal dialysis, N0 number of patients prevalent at the start of the 5-year time interval, N1 number of incident patients entering the haemodialysis patient population during each year, and PY projected total haemodialysis patient-years summed over the 5 years of the analysis period.